-
-
Small Molecule Drug Platforms
-
Chiral Catalysis Technology
-
Continuous Flow Technology
-
Fluorine Chemistry
-
Enzyme Catalysis
-
Photocatalysis
-
Solid-State Research
显示更多 -
-
Drug Product (DP) Platforms
-
Sustained and Controlled Release
-
Solubility Enhancement
-
Topical Formulation
-
Liquid Formulation
-
Softgels
-
Oral Fast Dissolving Technology
显示更多 -
-
Peptide Platforms
显示更多 -
Research Team
-
Jiuzhou Pharma Wins the 25th China Patent Excellence Award
Release time:
2025-06-06

Recently, the National Intellectual Property Administration announced the winners of the 25th China Patent Awards. Jiuzhou Pharma won the China Patent Excellence Award for its invention patent, "Asymmetric Hydrogenation Reaction of α-Keto Acid Compounds" (Patent No.: ZL201410468805.9). This follows last year’s achievement when Jiuzhou Pharma's "Halogenated S-(Perfluoroalkyl)-Dibenzothiophene Salt and Its Preparation Method" was awarded the 24th China Patent Excellence Award, marking another breakthrough for Jiuzhou Pharma in the field of intellectual property.
The China Patent Award is an authoritative award jointly organized by the National Intellectual Property Administration and the World Intellectual Property Organization (WIPO). It is the only government award in China that recognizes granted patent inventions and creations, representing the highest honor in the field of Chinese patents.
The awarded patent "Asymmetric Hydrogenation Reaction of α-Keto Acid Compounds" focuses on the direct catalysis of asymmetric hydrogenation of α-keto acid compounds using metal iridium chiral helical ligand complexes. This technology has successfully filled the technical gap in the asymmetric hydrogenation of α-keto acid compounds by metal-ligand complexes, offering significant advantages such as reduced catalyst usage, excellent catalytic efficiency, and outstanding stereoselectivity. It opens a new path for the synthesis of drugs and natural products containing α-hydroxy acid chiral building blocks. The resulting chiral α-hydroxy acid compounds, as key intermediates in natural products and pharmaceuticals, demonstrate enormous potential in pharmaceutical, chemical, and related industries.
More importantly, this patented technology has strongly supported the journey of the first domestically produced Class 1 anti-lung cancer drug from research and development to commercialization. With the help of this technology, the cost of chiral intermediates has been reduced by more than 50%, significantly improving the accessibility of anti-tumor drugs and allowing more patients worldwide to benefit. Additionally, this technology plays a crucial role in the design and development of new molecules for innovative drugs such as anti-tumor and anti-infection treatments, effectively promoting the high-quality development of the pharmaceutical manufacturing industry and generating significant social benefits.
This award is not only a strong recognition of Jiuzhou Pharma's technological innovation capabilities but also a full acknowledgment of the company's relentless efforts in intellectual property creation, protection, and utilization. Over the years, Jiuzhou Pharma has always regarded intellectual property as a core driving force for the company's development, continuously increasing investment in research and development, and focusing on independent innovation. As of 2024, the company has accumulated 310 international and domestic patents, forming a strong technological barrier and market competitiveness.
Looking to the future, Jiuzhou Pharma will continue to improve its intellectual property management system, constantly explore and break through core technologies, and make every effort to cultivate high-value patents. At the same time, the company will further strengthen the protection and conversion of intellectual property, driving the enterprise toward high-quality, sustainable development and injecting continuous vitality into the innovative development of the pharmaceutical industry.
Other News
Business Collaboration
Innovative Drug CDMO Services
Tel: 86-576-85588039 / 86-576-85580090
E-mail: bd@jiuzhoupharma.com
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
Business Collaboration
Innovative Drug CDMO Services
Tel: 86-576-85588039 / 86-576-85580090
E-mail: bd@jiuzhoupharma.com
Established Business Services(API)
Tel: 86-576-88881561
E-mail: bd@jiuzhoupharma.com